
PRCT Stock Forecast & Price Target
PRCT Analyst Ratings
Bulls say
PROCEPT BioRobotics is supported by improving commercial execution, as HYDROS accounts generated procedure volumes more than 35% higher than legacy AquaBeam accounts in 3Q26, signaling stronger utilization from the newer installed base. The replacement program is also ahead of expectations, with 20 replacement systems placed in the quarter and 36 YTD, while approximately 70% of systems were launched by the dedicated launch team and handpiece sales returned to above a 1:1 ratio with procedures, suggesting inventory normalization has stabilized. Strong new-system ASP of about $495k and international revenue growth of 32% y/y further reinforce the outlook, with upside tied to continued utilization gains and the growing mix of HYDROS across the installed base.
Bears say
PROCEPT BioRobotics is facing a weaker-than-expected growth backdrop, as 3Q26 sales of $98.3mn missed consensus and U.S. procedure utilization remained down ~9% y/y, underscoring soft demand for its core Aquablation franchise. New-system placements were especially concerning, with only 42 new systems sold versus an estimated 54, while 140 YTD U.S. net additions and the need for ~70 greenfield systems in 4Q26 to exceed the full-year target highlight elevated execution risk. Despite gross margin of 66.3% and solid handpiece sales, the company’s negative outlook is driven by compressed EBITDA margins, dependency on a sharp 4Q step-up, and rising competitive and reimbursement pressure from PAE.
This aggregate rating is based on analysts' research of PROCEPT BioRobotics Corp and is not a guaranteed prediction by Public.com or investment advice.
PRCT Analyst Forecast & Price Prediction
Start investing in PRCT
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About PROCEPT BioRobotics Corp (PRCT) Forecast
PRCT Analyst Forecast & Price Prediction
Start investing in PRCT
Order type
Buy in
Order amount
Est. shares
0 shares